Search

everythinglearnresearchcommunity

for

Search:↓

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Both topical calcipotriol and narrowband UVB improved alopecia, but combining them didn't enhance the effect on hair loss severity, despite higher vitamin D3 levels.

Combining calcipotriol with mometasone is more effective for treating alopecia areata than using mometasone alone.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.

People with Alopecia areata often have lower vitamin D levels, which may be linked to the severity of their condition.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

PRP treatment may help with alopecia areata, especially in newer cases.

The fractional carbon dioxide laser is a safe and effective treatment for alopecia areata and works better than betamethasone valerate cream alone.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

AB+ blood group is more common in alopecia areata patients.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.

A woman lost all her hair after mild COVID-19, but it started to regrow after treatment with a specific medication.

Latanoprost 0.005% solution safely increases hair density and regrowth in scalp alopecia areata.

Patients with alopecia areata may have lower vitamin D levels than healthy people.

Dupilumab helped a woman with severe hair loss regrow her hair quickly and maintain it for six months after stopping treatment.

Low vitamin D might be one of several factors involved in the hair loss condition alopecia areata.

Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.

Alopecia Areata is an autoimmune condition causing hair loss, influenced by genetics, environment, and possibly improved by anti-MIF therapy, with many patients experiencing regrowth within a year.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Using minoxidil and tofacitinib together can effectively treat severe hair loss.